Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Exclusion Criteria

• •1. Acute promyelocytic leukemia (APL) or acute megakaryocytic leukemia (AML-FAB M7).
• •2. AML with adverse cytogenetic risk according to the MRC 2010 classification.
• •3. AML arising from myelodysplastic syndromes, myeloproliferative disorders or chronic myelo-monocytic leukemia according to WHO classification (2016).
• •4. AML with Philadelphia chromosome or with BCR-ABL1.
• •5. Known active central nervous system leukemia
• •6. Previous anti-AML treatment other than hydroxyurea.
• •7. Cumulative anthracycline dose equivalent to ≥550 mg/m².
• •8. Treatment with an investigational drug within 30 days or 5 half-life whichever is longer, preceding the first dose of study medication.
• •9. Prior history of cancer unless controlled for at least 2 years and except for basal cell carcinoma, non-melanoma skin cancer and in situ cervical carcinoma.
• •10. Severe medical or mental condition precluding the administration of protocol treatments
• •11. Any sign of active uncontrolled disease including but not restricted to cardiac disease, infections, hepatitis.
• •12. Any severe chronic disease potentially interfering with the protocol including HIV infection, active hepatitis B or C.
• •13. Any severe conditions inducing contra-indications to dexamethasone including uncontrolled diabetes, infections, hypertension, stomach ulcer, mental illness, myasthenia or glaucoma.
• •14. Any serious medical condition, laboratory abnormality, or psychiatric illness that would place the participant at an unacceptable risk or prevent them from giving informed consent.
• •15. Known active HIV, Hepatitis B or C infection.
• •16. Pregnancy or breastfeeding.
• •17. Patients who are incapacitated, under wardship, legal guardianship, or under the protection of the courts.
• •18. Patients under State Medical Assistance (AME).